Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rottapharm Madaus and Selvita have entered into a drug discovery services contract to deliver Rottapharm Madaus a set of designed and synthesised compounds, including their optimised synthesis route, which is expected to have a therapeutic potential in an indicated area.
Subscribe to our email newsletter
Luigi Stasi, director of medicinal chemistry department at Rottapharm, said: “We are delighted to start an FTE-based collaboration with Selvita. We are keen to take advantage of Selvita’s know-how to support the progression of our drug discovery pipeline. We are looking forward to a very fruitful and effective cooperation.”
Pawel Przewiezlikowski, CEO of Selvita, said: “We are very pleased and honoured that we can cooperate with Rottapharm Madaus. Working for Rottapharm Madaus on this project is expected to enable us to take a full advantage of our scientists and new facilities, and I truly believe we can deliver exactly what Rottapharm Madaus needs. I’m looking forward to this cooperation very much.”
Rottapharm R&D is focused on therapeutic areas such as: rheumatology, gynaecology, urology, gastroenterology, bronchopneumology, psychiatry and oncology.
Selvita Group is a Polish, privately-owned, biotechnology company engaged in the drug discovery services.